Literature DB >> 19381077

Sustained release of microbicides by newly engineered vaginal rings.

Brij B Saxena1, Young A Han, Dingyi Fu, Premila Rathnam, Mukul Singh, Jeffrey Laurence, Sidney Lerner.   

Abstract

OBJECTIVE: An effective vaginal microbicide against sexual HIV transmission remains elusive, with requirements for adherence to appropriate application of effective, nontoxic products being a major deterrent. We explored methods to enable sustained release of combinations of antiretroviral microbicides, utilizing intravaginal rings composed of biosoluble Acacia gum or nonbiodegradable hydrogel of 2-hydroxyethyl methacrylate and sodium methacrylate, materials approved for use by the US Food and Drug Administration. DESIGN AND METHODS: The reverse transcriptase inhibitors TMC120, PMPA, 3'-azido-3'-deoxythymidine, and a newly characterized anti-HIV agent, Boc-lysinated betulonic acid, were incorporated into vaginal rings with different combinations. Daily and cumulative release rates of these inhibitors in ring eluates were determined by high-performance liquid chromatography, gas chromatography, or immunoassay. Anti-HIV effects were measured by assessment of p24 Gag antigen in T-cell cultures exposed to HIV-1 isolates.
RESULTS: Drug release rates were sustained at concentrations higher than the minimum effective dose for HIV inhibition. The release was maintained for no less than 15 and 28 days from the Acacia gum and 2-hydroxyethyl methacrylate and sodium methacrylate rings, respectively. Boc-lysinated betulonic acid showed more than 90% inhibition of HIV-1 infection in H9 cells, with little toxicity to normal cells.
CONCLUSION: The intravaginal rings described here are capable of efficacious drug delivery. Incorporation of several antiretroviral agents, including betulinol derivatives, which act at multiple levels of the HIV life cycle, may provide a synergistic effect to achieve higher efficacy on the inhibition of HIV infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19381077     DOI: 10.1097/QAD.0b013e32832af57c

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  17 in total

1.  Sensitive and rapid HPLC quantification of tenofovir from hyaluronic acid-based nanomedicine.

Authors:  Vivek Agrahari; Bi-Botti C Youan
Journal:  AAPS PharmSciTech       Date:  2012-01-04       Impact factor: 3.246

2.  Joining forces.

Authors:  Cassandra Willyard
Journal:  Nature       Date:  2010-07-15       Impact factor: 49.962

3.  Engineering a degradable polyurethane intravaginal ring for sustained delivery of dapivirine.

Authors:  Manpreet Kaur; Kavita M Gupta; Azadeh E Poursaid; Prasoona Karra; Alamelu Mahalingam; Hyder A Aliyar; Patrick F Kiser
Journal:  Drug Deliv Transl Res       Date:  2011-06       Impact factor: 4.617

4.  Development and Characterization of a Vaginal Film Containing Dapivirine, a Non- nucleoside Reverse Transcriptase Inhibitor (NNRTI), for prevention of HIV-1 sexual transmission.

Authors:  Ayman Akil; Michael A Parniak; Charlene S Dezzuitti; Bernard J Moncla; Marilyn R Cost; Mingguang Li; Lisa Cencia Rohan
Journal:  Drug Deliv Transl Res       Date:  2011-06-01       Impact factor: 4.617

5.  Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring.

Authors:  John A Moss; Amanda M Malone; Thomas J Smith; Sean Kennedy; Etana Kopin; Cali Nguyen; Josh Gilman; Irina Butkyavichene; Kathleen L Vincent; Massoud Motamedi; David R Friend; Meredith R Clark; Marc M Baum
Journal:  Antimicrob Agents Chemother       Date:  2011-11-28       Impact factor: 5.191

6.  Safety and pharmacokinetics of intravaginal rings delivering tenofovir in pig-tailed macaques.

Authors:  John A Moss; Amanda M Malone; Thomas J Smith; Irina Butkyavichene; Cassandra Cortez; Joshua Gilman; Sean Kennedy; Etana Kopin; Cali Nguyen; Preetha Sinha; R Michael Hendry; Patricia Guenthner; Angela Holder; Amy Martin; Janet McNicholl; James Mitchell; Chou-Pong Pau; Priya Srinivasan; James M Smith; Marc M Baum
Journal:  Antimicrob Agents Chemother       Date:  2012-09-10       Impact factor: 5.191

7.  A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis.

Authors:  Todd J Johnson; Meredith R Clark; Theodore H Albright; Joel S Nebeker; Anthony L Tuitupou; Justin T Clark; Judit Fabian; R Tyler McCabe; Neelima Chandra; Gustavo F Doncel; David R Friend; Patrick F Kiser
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

8.  Extension into the entrance channel of HIV-1 reverse transcriptase--crystallography and enhanced solubility.

Authors:  Mariela Bollini; Kathleen M Frey; José A Cisneros; Krasimir A Spasov; Kalyan Das; Joseph D Bauman; Eddy Arnold; Karen S Anderson; William L Jorgensen
Journal:  Bioorg Med Chem Lett       Date:  2013-07-08       Impact factor: 2.823

9.  Hyaluronidase-sensitive nanoparticle templates for triggered release of HIV/AIDS microbicide in vitro.

Authors:  Vivek Agrahari; Chi Zhang; Tao Zhang; Wenjing Li; Todor K Gounev; Nathan A Oyler; Bi-Botti C Youan
Journal:  AAPS J       Date:  2013-12-17       Impact factor: 4.009

10.  Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.

Authors:  Mariela Bollini; José A Cisneros; Krasimir A Spasov; Karen S Anderson; William L Jorgensen
Journal:  Bioorg Med Chem Lett       Date:  2013-07-08       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.